On July 9, 2024, the IND application of ZHB103 Injection, a Class 1 new drug of therapeutic biological products, which was originally developed by ZONHONBIO, with full independent intellectual property rights both at home and abroad, was formally approved by the FDA. The approved indication is transient ischemic attack or mild ischemic stroke.